Enveric Biosciences (ENVB) Non-Current Assets (2011 - 2026)
Enveric Biosciences (ENVB) posted Non-Current Assets of $146365.0 for Q1 2026, down 8.08% sequentially from $159234.0 in Q4 2025, and down 45.24% YoY from $267279.0 in Q1 2025.
Enveric Biosciences (ENVB) Non-Current Assets (2011 - 2026) Analysis & Trends
Enveric Biosciences has reported Non-Current Assets for 13 years, with the latest figure at $146365.0 in Q1 2026.
- Quarterly Non-Current Assets fell 45.24% year-over-year to $146365.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146365.0 (down 45.24% YoY) and the FY2025 annual result came in at $159234.0, down 54.24% from the prior year.
- Non-Current Assets fell to $146365.0 in Q1 2026 per ENVB's latest filing, from $159234.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $9.5 million in Q1 2022 and troughed at $146365.0 in Q1 2026.
- A 5-year average of $2.0 million and a median of $620972.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 321.07% in 2022, then sank 90.78% in 2023.
- Over 5 years, Non-Current Assets stood at $1.1 million in 2022, then sank by 35.92% to $718309.0 in 2023, then sank by 51.56% to $347959.0 in 2024, then sank by 54.24% to $159234.0 in 2025, then retreated by 8.08% to $146365.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $146365.0, $159234.0, and $196521.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | 150,674.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146,365.00 |
| Dec 31, 2025 | 159,234.00 |
| Sep 30, 2025 | 196,521.00 |
| Jun 30, 2025 | 241,082.00 |
| Mar 31, 2025 | 267,279.00 |
| Dec 31, 2024 | 347,959.00 |
| Sep 30, 2024 | 452,057.00 |
| Jun 30, 2024 | 531,670.00 |
| Mar 31, 2024 | 620,972.00 |
| Dec 31, 2023 | 718,309.00 |
| Sep 30, 2023 | 792,272.00 |
| Jun 30, 2023 | 900,151.00 |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 8.59 Mn |
| Jun 30, 2022 | 9.20 Mn |
| Mar 31, 2022 | 9.51 Mn |
| Dec 31, 2021 | 8.98 Mn |
| Sep 30, 2021 | 47.48 Mn |
| Jun 30, 2021 | 2.19 Mn |